Featured News

Thank you to everyone who participated in the CDF Bid for a Cure Online Auction! All money raised will directly accelerate celiac disease research.

Researchers at Boston Children’s Hospital are evaluating access to gluten-free food prior to and during the COVID-19 pandemic. We invite anyone with celiac disease following a gluten-free diet to complete this 3-5 minute survey.

Periodically, the FDA hosts workshops to help researchers understand exactly what the FDA will be looking for (aka “endpoints”) when evaluating the efficacy of a proposed drug.

Researchers at MassGeneral Hospital for Children have found substantial gut microbiome changes in the intestines of at-risk infants before celiac disease onset.

The overall prevalence of celiac disease was found to be 1.6% - a much greater percentage than the 1% that researchers have been approximating for years.

Cabinet Health, a verified gluten-free OTC medicine company, announced their partnership with the Celiac Disease Foundation in order to better support the needs of the celiac community.

A recent study published in JAMA Network, using two decades worth of dietary data, concluded that gluten consumption in people without celiac disease did not impair cognitive function.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.